ERBB2 and breast carcinoma: The breast cancer subtype was HR+/HER2− (luminal A) in 52.7% of patients, HR+/HER2+ (luminal B) in 11.2%, HR−/HER2+ (HER2 enriched) in 2.8% and HR−/HER2− (triple negative) in 2.7%.